TFF Pharmaceuticals (NASDAQ:TFFP) Trading Up 8.9%

Shares of TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) traded up 8.9% during trading on Monday . The company traded as high as $1.95 and last traded at $1.95. 12,254 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 34,674 shares. The stock had previously closed at $1.79.

TFF Pharmaceuticals Stock Performance

The stock has a market cap of $6.04 million, a price-to-earnings ratio of -0.19 and a beta of 1.36. The business’s fifty day simple moving average is $1.92 and its 200 day simple moving average is $3.22.

TFF Pharmaceuticals (NASDAQ:TFFP) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($1.22) EPS for the quarter, topping analysts’ consensus estimates of ($1.70) by $0.48. TFF Pharmaceuticals had a negative net margin of 1,612.73% and a negative return on equity of 225.15%. The firm had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.15 million. As a group, analysts forecast that TFF Pharmaceuticals, Inc. will post -4.28 EPS for the current fiscal year.

Hedge Funds Weigh In On TFF Pharmaceuticals

An institutional investor recently bought a new position in TFF Pharmaceuticals stock. Armistice Capital LLC acquired a new position in TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 185,695 shares of the company’s stock, valued at approximately $308,000. Armistice Capital LLC owned approximately 5.99% of TFF Pharmaceuticals at the end of the most recent reporting period. 15.25% of the stock is owned by institutional investors and hedge funds.

TFF Pharmaceuticals Company Profile

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.